Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T08:17:41.910Z Has data issue: false hasContentIssue false
  • English
  • Français

A Comparison of Piribedil, Procyclidine and Placebo in the Control of Phenothiazine-induced Parkinsonism

Published online by Cambridge University Press:  29 January 2018

R. H. S. Mindham ,
Pauline Lamb  and
Rachel Bradley
R. H. S. Mindham
Affiliation:
University Department of Psychiatry, Mapperley Hospital, Nottingham NG3 6AA
Pauline Lamb
Affiliation:
Mapperley Hospital, Nottingham
Rachel Bradley
Affiliation:
St Ann's Hospital, Nottingham
Get access Rights & Permissions [Opens in a new window]

Summary

A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia. Procyclidine was shown to be more effective and piribedil less effective than the placebo. Piribedil produced a number of unpleasant effects, including headache, vomiting and malaise.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 130 , Issue 6 , June 1977 , pp. 581 - 585
Copyright
Copyright © Royal College of Psychiatrists, 1977 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cahan, R. B. & Parrish, D. D. (1960) Reversibility of drug-induced Parkinsonism. American Journal of Psychiatry, 116, 1022–3.CrossRefGoogle ScholarPubMed
Corrodi, H., Fuxe, K. & Ungerstedt, U. (1971) Evidence for a new type of dopamine receptor stimulating agent. Journal of Pharmacy and Pharmacology, 23, 989–91.Google Scholar
Ekdawi, M. Y. & Fowke, R. (1966) A controlled trial of Anti-Parkinson drugs in drug-induced Parkinsonism. British Journal of Psychiatry, 112, 633–6.Google Scholar
Johnson, D. A. W. (1973) The side-effects of fluphenazine decanoate. British Journal of Psychiatry, 123, 519–22.Google Scholar
Klawans, H. L. (1973) The pharmacology of tardive dyskinesias. American Journal of Psychiatry, 130, 82–6.Google Scholar
McClelland, H. A., Blessed, G., Bhate, S., Ali, N. & Clarke, P. A. (1974) The abrupt withdrawal of anti-parkinsonian drugs in schizophrenia patients. British Journal of Psychiatry, 124, 151–9.CrossRefGoogle Scholar
Mandel, W. & Oliver, W. A. (1961) Withdrawal of maintenance anti-Parkinson drug in the phenothiazine-induced extra-pyramidal reaction. American Journal of Psychiatry, 118, 350–1.Google Scholar
Meier, M.J. & Martin, W. E. (1970) Measurement of behavioural changes in patients on ‘l-DOPA’. Lancet, i, 352–3.Google Scholar
Mindham, R. H. S., Gaind, R., Anstee, B. H. & Rimmer, R. (1972) Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychological Medicine, 2, 406–13.Google Scholar
Mindham, R. H. S. (1976) The assessment of drug-induced extrapyramidal reactions and of drugs given for their control. British Journal of Clinical Pharmacology, 3, 395–400.Google Scholar
Singh, M. M. & Kay, S. R. (1975) Therapeutic reversal with benztropine in schizophrenics—practical and theoretical significance. Journal of Nervous and Mental Disease, 169, 258–66.Google Scholar
Strang, R. R. (1965) Kemadrin in the treatment of Parkinsonism: a double-blind and one-year follow-up study. Current Medicine and Drugs, 5, No. 8, 27–32.Google ScholarPubMed
Vakil, S. D., Calne, D. B., Reid, J. L. & Seymour, C. A. (1973) Pyrimidyl-piperonyl-piperazine (ET495) in Parkinsonism. Advances in Neurology, 3, 121–5.Google Scholar
Westlake, R. J. & Rastegar, A. (1973) Hyperpyrexia from drug combinations. Journal of American Medical Association, 225, 1250.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.